



# Verona Pharma

9 August 2016

## Director Dealing

RNS Number : 7030G

Verona Pharma PLC

09 August 2016

### Verona Pharma plc

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	Dr. Jan-Anders Karlsson
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Verona Pharma plc
b)	LEI	n/a

<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares of 0.1 pence each  GB00B06GSH43	
b)	Nature of the transaction	Jan-Anders Karlsson purchased 600,000 Ordinary Shares	
c)	Price(s) and volume(s)	<b>Price(s)</b>	<b>Volume(s)</b>
		3.249 pence per Ordinary Share	600,000 Ordinary Shares
d)	Aggregated information  - Aggregated volume  - Price	600,000 Ordinary Shares at 3.249 pence per Ordinary Share	
e)	Date of the transaction	9 August 2016	
f)	Place of the transaction	London Stock Exchange, AIM	

This information is provided by RNS  
The company news service from the London Stock Exchange

END

DSHSSLFDUFMSEFA

**Verona Pharma plc**

Jan-Anders Karlsson, CEO  
Victoria Stewart, Director of Communications  
Tel: +44 (0)20 3283 4200  
info@veronapharma.com

**N+1 Singer (Nominated Adviser and UK Broker)**

Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)  
Brough Ransom /Mia Gardner (Corporate Broking)  
Tel: +44 (0)20 3283 4200

**Optimum Strategic Communications**

(European Media and Investor enquiries)  
Mary Clark, Annemarieke Ezendam  
Hollie Vile  
Tel: +44 (0) 203 922 0891  
verona@optimumcomms.com

**Westwicke, an ICR Company (Investor enquiries)**

Stephanie Carrington  
Tel. +1 646-277-1282  
Stephanie.Carrington@icrinc.com

---

**About Verona Pharma plc**

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 has also shown anti-inflammatory effects and been well tolerated in clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

**Forward Looking Statements**

**This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.**

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the development of DPI and MDI formulations of RPL554 and the potential for these formulations to increase the market opportunity for the product, if approved.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the

date of this press release.

---

Content downloaded from <http://www.veronapharma.com/> on 18th July, 2019 at 09:48am.